The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a $391,250 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate fibrinogen as a potential mediator of COVID-19-associated coagulopathy. The award aims to define the impact of therapeutic plasma exchange on blood rheology and vascular integrity in COVID-19 patients, as well as examine the role of a unique fibrinogen isoform in thrombosis. This research could advance the understanding of critical illness and acute coagulopathy in COVID-19, and potentially have relevance for post-acute sequelae of SARS-CoV-2 infection (PASC) and other thromboinflammatory conditions. The award provides funding from March 1, 2025 through February 29, 2028 to support this series of experiments led by the principal investigator at Emory University.
Generated 3/18/25, 2:56 AM